Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
3.34
0.00 (0.00%)
Real-time:   3:55PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.83 - 5.01
Open     -
Vol / Avg. 0.00/18,273.00
Mkt cap 31.94M
P/E     -
Div/yield     -
EPS -0.01
Shares 9.56M
Beta -0.15
Inst. own 17%
Aug 7, 2014
Q2 2014 Chembio Diagnostics Inc Earnings Call - 10:00AM EDT - Add to calendar
Aug 7, 2014
Q2 2014 CHEMBIO DIAGNOSTICS INC Earnings Release - 9:30AM EDT - Add to calendar
Jun 19, 2014
CHEMBIO DIAGNOSTICS INC Annual Shareholder Meeting
May 8, 2014
Q1 2014 CHEMBIO DIAGNOSTICS INC Earnings Conference Call
May 8, 2014
Q1 2014 CHEMBIO DIAGNOSTICS INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -3.87% 1.80%
Operating margin -6.58% 3.40%
EBITD margin - 5.46%
Return on average assets -3.76% 2.54%
Return on average equity -4.47% 3.12%
Employees 206 -
CDP Score - -

Address

3661 Horseblock Road
MEDFORD, NY 11763
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Chembio Diagnostics, Inc. develops, manufactures and markets rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company´┐Żs main products are four rapid tests for the detection of human immunodeficiency virus (HIV) antibodies. Three of these products employ lateral flow technology, can be used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format, and a barrel format. The tests employing the cassette and barrel formats were approved by the United States Food and Drug Administration (FDA) and are distributed by Inverness Medical Innovations, Inc. (Inverness) in the United States. Its fourth rapid HIV test, which is developed on its Dual Path Platform (DPP) technology, detects antibodies to HIV in oral fluid samples, as well as all blood matrices.

Officers and directors

John J. Sperzel III President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Sharon Klugewicz Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Javan Esfandiari Executive Vice President - Research and Development
Age: 47
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 50
Bio & Compensation  - Reuters
Katherine L. Davis Non-Executive Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barbara A. DeBuono M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Gary Meller M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters